AELIS.PA - Aelis Farma SA
| Previous close | 14.00 |
| Open | 13.95 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 13.95 - 14.00 |
| 52-week range | 8.56 - 14.28 |
| Volume | |
| Avg. volume | 670 |
| Market cap | 175.017M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.21 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 21.30 |
Business WireResults of Aelis Farma Combined General Meeting of May 24, 2023
BORDEAUX, France, May 25, 2023--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, announces that all the resolutions recommended by the Board of directors were adopted by the Combined General Meeting of shareholders.
- Business Wire
Aelis Farma: Combined General Meeting of May 24, 2023: Availability of Preparatory Documents and Participation and Voting Procedures
BORDEAUX, France, May 02, 2023--Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, PEA-PME eligible) (Paris: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, informs its shareholders and the financial community that the Company’s Combined General Meeting will be held on Wednesday, May 24, 2023, at 2 p.m., at 1 rue Lafaurie de Mondabon, 33000 Bordeaux.
- Business Wire
Aelis Farma: Publication of the 2022 Universal Registration Document
BORDEAUX, France, April 27, 2023--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS) (Paris: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, announces the publication of its 2022 Universal Registration Document (URD) approved by the French Financial Markets Authority (Autorité des Marchés Financiers (AMF)) on April 26, 2023, under number R.23-018.
Business WireDegroof Petercam Initiates the Coverage of Aelis Farma With a "Buy" Recommendation
BORDEAUX, France, April 24, 2023--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS) (Paris:AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today announces the publication of an initiation report by Degroof Petercam, an independent Belgian-rooted investment bank.
Business WireAelis Farma Reports Its 2022 Annual Financial Results and Confirms Its 2023 Outlook
BORDEAUX, France, April 03, 2023--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, PEA-PME eligible) (Paris: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today announced its annual results for the year to December 31, 2022.
Business WireAelis Farma Has Participated in Two Symposiums Marking World Down Syndrome Day
BORDEAUX, France, March 21, 2023--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, eligible for PEA-PME equity savings plans) (Paris:AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today announces its participation in two symposiums marking World Down Syndrome Day.
- Business Wire
Aelis Farma Announces its 2023 Financial Calendar
BORDEAUX, France, January 31, 2023--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, PEA-PME eligible) (Paris: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, today announces its indicative financial calendar for the financial year 2023.
- Business Wire
Aelis Farma Announces the Recruitment of the First Patient for the Phase 1/2 Clinical Trial of Its Drug Candidate AEF0217 for the Treatment of Cognitive Disorders in Down Syndrome
BORDEAUX, France, December 16, 2022--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, announces today the recruitment of the first patient for its phase 1/2 trial of AEF0217 in participants with Down syndrome.
Business WireAelis Farma Announces Positive Results From Its Safety Trials in Healthy Volunteers and the Authorization to Start the First Trial in People with Down Syndrome with AEF0217, its Drug Candidate for the Treatment of Cognitive Disorders
BORDEAUX, France, November 15, 2022--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, PEA-PME eligible) (Paris: AELIS), a clinical stage biopharmaceutical company specializing in the development of treatments for brain diseases, announces today positive results from its phase 1 clinical trials in healthy volunteers with its drug candidate AEF0217. AEF0217 is being developed for the treatment of cognitive deficits caused by a hyperactivity of the CB1 receptor, and as a first indi
Business WireAelis Farma CEO Pier Vincenzo Piazza Receives the EY Entrepreneur of the Year Award
BORDEAUX, France, October 04, 2022--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, announces today that Pier Vincenzo Piazza, CEO of Aelis Farma, has received the Entrepreneur of the Year 2022 award from auditing and consulting firm Ernst and Young, in the "Scale-Up" category.
Business WireAelis Farma: Availability of the 2022 Half-year Financial Report
BORDEAUX, France, September 27, 2022--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 - ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today announces that its half-year financial report has been made available to the public and filled with the French Financial Markets Authority (Autorité des marchés financiers).
- Business Wire
Aelis Farma reports 2022 half-year financial results and confirms its development objectives
BORDEAUX, France, September 26, 2022--Regulatory News: Aelis Farma (Paris: AELIS)(ISIN: FR0014007ZB4 - ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today announces its half-year results for the period ended June 30, 2022 and takes stock of its development.
- Business Wire
Aelis Farma Will Participate in the Addiction 2022 Conference Dedicated to Innovation in the Treatment of Addictions
BORDEAUX, France, September 22, 2022--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 - ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today announces its participation as a speaker at the Addiction 2022 international conference to be held from September 25 to 28, 2022 in Sardinia, Italy.
- Business Wire
Aelis Farma: Ordinary General Meeting of June 28, 2022: Availability of Preparatory Documents and Participation and Voting Procedures
BORDEAUX, France, June 07, 2022--Regulatory News: Aelis Farma (ISIN code: FR0014007ZB4 – ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases (the « Company »), informs its shareholders and the financial community that the Company’s Ordinary General Meeting will be held on Tuesday, June 28, 2022 at 2 p.m., at Centre Broca Nouvelle Aquitaine, 11 rue Albert Marquet, 33000 Bordeaux.